WNDM is nearing the completion stage of its registration of CellerateRX in Mexico and has identified its first distributor in that country. CellerateRX® is FDA cleared for acute and chronic wounds which include but are not limited to: diabetic ulcers, venous stasis ulcers, ulcers due to arterial insufficiency, pressure ulcers stages I-IV, surgical wounds, traumatic wounds, superficial wounds, and 1st and 2nd degree burns
"The fact that international recognition for CellerateRX is increasing is very encouraging and reinforces what we have believed for a long time and that is that we have the best product in the market for the management of diabetic wounds," says Deborah Jenkins Hutchinson, President of Wound Management Technologies, Inc.
Best Damn Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move.
Sign Up for our Free Stock Newsletter
Wound Management Technologies, Inc., through its subsidiary, Wound Care Innovations, LLC, distributes collagen-based wound care products in the United States
Sign up for the free Best Damn Penny Stocks newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website
About Best Damn Penny Stocks
Best Damn Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer
